2024
The Scope of Multimorbidity in Family Medicine: Identifying Age Patterns Across the Lifespan
Chartash D, Gilson A, Taylor R, Hart L. The Scope of Multimorbidity in Family Medicine: Identifying Age Patterns Across the Lifespan. The Journal Of The American Board Of Family Medicine 2024, 37: 251-260. PMID: 38740476, DOI: 10.3122/jabfm.2023.230221r1.Peer-Reviewed Original ResearchConceptsRates of multimorbidityICD-10 diagnostic codesFamily medicine clinicPresence of multimorbidityHealth care systemCardiometabolic disordersMedical historyStudy periodMultimorbidity rateMultimorbidity indexGroup of diagnosesPatient transitionsFamily medicineGeriatric careRetrospective cohort studyCare systemMental healthMultimorbidityMedicine clinicDiagnostic codesPractical resourcesAlcohol use disorderCohort studyAged 0Age groups
2022
Epigenome‐wide association study of BMI in Black populations from InterGEN and GENOA
Taylor J, Huang Y, Zhao W, Wright M, Wang Z, Hui Q, Potts‐Thompson S, Barcelona V, Prescott L, Yao Y, Crusto C, Kardia S, Smith J, Sun Y. Epigenome‐wide association study of BMI in Black populations from InterGEN and GENOA. Obesity 2022, 31: 243-255. PMID: 36479596, PMCID: PMC10107734, DOI: 10.1002/oby.23589.Peer-Reviewed Original ResearchConceptsObesity-associated conditionsSignificant public health concernAssociation of BMIPeripheral blood samplesLinear mixed-effects regression modelsBlack populationPublic health concernMixed-effects regression modelsBlack womenCross-sectional analysisEpigenome-wide DNA methylationIllumina EPIC BeadChipDevelopment of diseaseCardiometabolic disordersDiscovery cohortBlood samplesBMIHigh incidenceEarly onsetGENOA studyObesityHealth concernCohortDNAm sitesDNA methylationCardiometabolic disorders, inflammation and the incidence of non-alcoholic fatty liver disease: A longitudinal study comparing lean and non-lean individuals
Aneni E, Saeed G, Bittencourt M, Cainzos-Achirica M, Osondu C, Budoff M, Parise E, Santos R, Nasir K. Cardiometabolic disorders, inflammation and the incidence of non-alcoholic fatty liver disease: A longitudinal study comparing lean and non-lean individuals. PLOS ONE 2022, 17: e0266505. PMID: 35385529, PMCID: PMC8985996, DOI: 10.1371/journal.pone.0266505.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseRisk of NAFLDElevated blood glucoseElevated blood pressureFatty liver diseaseBlood glucoseLean individualsBlood pressureCardiometabolic disordersPhysical inactivityWaist circumferenceLiver diseaseDevelopment of NAFLDHigh-sensitivity C-reactive proteinCardiovascular disease risk stratificationSensitivity C-reactive proteinCardiometabolic risk factorsAlcohol Use Disorders Identification TestC-reactive proteinMain exposure variableDisease risk stratificationHospital Israelita Albert EinsteinDisorders Identification TestAppropriate preventive measuresAtherogenic dyslipidemia
2020
The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study
Aneni E, Bittencourt M, Teng C, Cainzos-Achirica M, Osondu C, Soliman A, Al-Mallah M, Buddoff M, Parise E, Santos R, Nasir K. The risk of cardiometabolic disorders in lean non-alcoholic fatty liver disease: A longitudinal study. American Journal Of Preventive Cardiology 2020, 4: 100097. PMID: 34327473, PMCID: PMC8315654, DOI: 10.1016/j.ajpc.2020.100097.Peer-Reviewed Original ResearchLean non-alcoholic fatty liver diseaseNon-alcoholic fatty liver diseaseFatty liver diseaseAlcohol Use Disorders Identification TestLean individualsAtherogenic dyslipidemiaElevated glucoseElevated BPLiver diseaseFatty liverCardiovascular risk stratificationYoung asymptomatic individualsHealth promotion evaluationDisorders Identification TestAppropriate preventive measuresMedian followNAFLD individualsCardiometabolic consequencesCardiometabolic disordersRisk stratificationAsymptomatic individualsHigh riskBlood samplesAnthropometric measuresPopulation cohort459-P: Liver-Targeted Mitochondrial Uncoupling by CRMP Improves Whole-Body Insulin Sensitivity and Attenuates Atherosclerosis in A LDLR-/- Mouse Model of Metabolic Syndrome
GOEDEKE L, ROTLLAN N, TOUSSAINT K, NASIRI A, ZHANG X, LEE J, ZHANG X, FERNÁNDEZ-HERNANDO C, SHULMAN G. 459-P: Liver-Targeted Mitochondrial Uncoupling by CRMP Improves Whole-Body Insulin Sensitivity and Attenuates Atherosclerosis in A LDLR-/- Mouse Model of Metabolic Syndrome. Diabetes 2020, 69 DOI: 10.2337/db20-459-p.Peer-Reviewed Original ResearchWhole-body insulin sensitivitySpouse/partnerInsulin sensitivityCardiovascular diseaseMetabolic syndromeAortic root plaque areaHigh fat-cholesterol dietLdlr-/- mouse modelTreatment of CVDEctopic lipid contentLDLR-/- micePeripheral insulin sensitivityNecrotic core areaType 2 diabetesAnti-atherogenic roleFibrous cap areaAdvisory PanelCRMP treatmentAttenuates AtherosclerosisCardiometabolic disordersFatty liverCholesterol dietInsulin resistanceNondiabetic individualsHepatic triglycerides
2013
Prescription of Second-Generation Antipsychotics: Responding to Treatment Risk in Real-World Practice
Hermes ED, Sernyak MJ, Rosenheck RA. Prescription of Second-Generation Antipsychotics: Responding to Treatment Risk in Real-World Practice. Psychiatric Services 2013, 64: 238-244. PMID: 23241613, DOI: 10.1176/appi.ps.201200183.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsProportion of patientsCardiometabolic riskCardiometabolic disordersCardiovascular diseaseSociodemographic dataSingle Veterans Affairs medical centerVeterans Affairs Medical CenterChoice of antipsychoticHigh cardiometabolic riskPatients' sociodemographic dataQuality of careAntipsychotic prescribedReal-world practicePsychiatric providersTreatment decisionsMedical CenterTreatment risksComorbid diagnosesPatientsAntipsychoticsSignificant associationModerate riskNew prescriptionsProvider sensitivity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply